Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison between success rates for smokers re-treated by a smokers' clinic and success rates for smokers treated for the first time

L. Stepankova, E. Kralikova, K. Zvolska, A. Pankova, Z. Adamcekova, M. Kuhn, D. Noland

. 2021 ; 116 (2) : 346-355. [pub] 20200718

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

AIMS: To compare success rates and characteristics of smokers treated a second time by a smokers' clinic with success rates of their first treatment. DESIGN: Retrospective cohort study. SETTING: Tobacco Dependence Treatment clinic in Prague, Czech Republic, between 2005 and 2017. PARTICIPANTS: A total of 5225 smokers treated either once (n = 5006, single treatment sample, SS) or also second time (n = 219, re-treated sample, RS), on average 4.47 years after the first visit. INTERVENTION: Smokers received intensive treatment of tobacco dependence with pharmacotherapy options. Outcomes were evaluated after 1 year. In case of failure or relapse, participants could undergo re-treatment in the same setting at least 1 year after the start of the first treatment. MEASUREMENTS: Twelve-month self-reported continuous abstinence; CO-validated (≤ 6 parts per million); number of visits; type of pharmacotherapy; mental health history; Fagerström Test for Cigarette Dependence; time between first and second treatment. RESULTS: The abstinence rate in the SS was 34.8% [95% confidence interval (CI) = 33.4%, 36.1%] and in the RS was 37% (95% CI = 30.6%, 43.8%) and 39.7% (95% CI = 33.2%, 45.5%) for their first and second treatments, respectively. The samples were comparable on smoking and socio-demographic characteristics and pharmacotherapy used, but the RS in the second treatment had a higher prevalence of diagnosed mental health disorder at 39.3% (95% CI = 32.8%; 46.1%) compared with 23.7% (95% CI = 22.5%; 24.9%) in the SS. Participants who initiated their second quit attempt 1 to 2 years after the first one were less successful than those who initiated their second quit attempt later (25 versus 43%; P < 0.05). The results of the first treatment cycle were not found to be a reliable predictor for outcomes of the second cycle of treatment in univariate or multivariate logistic regression (odds ratio = 1.35, 95% CI = 0.70-2.63, P = 0.373). CONCLUSION: In Prague, Czech Republic, smokers re-attending stop-smoking treatment more than 2 years after their previous quit attempt appear to achieve similar success rates to those being treated for the first time.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026093
003      
CZ-PrNML
005      
20211026133219.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/add.15175 $2 doi
035    __
$a (PubMed)32592219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stepankova, Lenka $u Centre for Tobacco Dependence, 3rd Medical Department, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
245    10
$a Comparison between success rates for smokers re-treated by a smokers' clinic and success rates for smokers treated for the first time / $c L. Stepankova, E. Kralikova, K. Zvolska, A. Pankova, Z. Adamcekova, M. Kuhn, D. Noland
520    9_
$a AIMS: To compare success rates and characteristics of smokers treated a second time by a smokers' clinic with success rates of their first treatment. DESIGN: Retrospective cohort study. SETTING: Tobacco Dependence Treatment clinic in Prague, Czech Republic, between 2005 and 2017. PARTICIPANTS: A total of 5225 smokers treated either once (n = 5006, single treatment sample, SS) or also second time (n = 219, re-treated sample, RS), on average 4.47 years after the first visit. INTERVENTION: Smokers received intensive treatment of tobacco dependence with pharmacotherapy options. Outcomes were evaluated after 1 year. In case of failure or relapse, participants could undergo re-treatment in the same setting at least 1 year after the start of the first treatment. MEASUREMENTS: Twelve-month self-reported continuous abstinence; CO-validated (≤ 6 parts per million); number of visits; type of pharmacotherapy; mental health history; Fagerström Test for Cigarette Dependence; time between first and second treatment. RESULTS: The abstinence rate in the SS was 34.8% [95% confidence interval (CI) = 33.4%, 36.1%] and in the RS was 37% (95% CI = 30.6%, 43.8%) and 39.7% (95% CI = 33.2%, 45.5%) for their first and second treatments, respectively. The samples were comparable on smoking and socio-demographic characteristics and pharmacotherapy used, but the RS in the second treatment had a higher prevalence of diagnosed mental health disorder at 39.3% (95% CI = 32.8%; 46.1%) compared with 23.7% (95% CI = 22.5%; 24.9%) in the SS. Participants who initiated their second quit attempt 1 to 2 years after the first one were less successful than those who initiated their second quit attempt later (25 versus 43%; P < 0.05). The results of the first treatment cycle were not found to be a reliable predictor for outcomes of the second cycle of treatment in univariate or multivariate logistic regression (odds ratio = 1.35, 95% CI = 0.70-2.63, P = 0.373). CONCLUSION: In Prague, Czech Republic, smokers re-attending stop-smoking treatment more than 2 years after their previous quit attempt appear to achieve similar success rates to those being treated for the first time.
650    _2
$a ambulantní zařízení $7 D000554
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a kuřáci $x statistika a číselné údaje $7 D000074285
650    _2
$a kouření $x epidemiologie $7 D012907
650    _2
$a odvykání kouření $x metody $7 D016540
650    _2
$a látky pro odvykání kouření $x terapeutické užití $7 D000077444
650    _2
$a prostředky pro ukončení závislosti na tabáku $x statistika a číselné údaje $7 D061485
650    _2
$a poruchy vyvolané užíváním tabáku $x terapie $7 D014029
650    _2
$a vareniklin $x terapeutické užití $7 D000068580
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kralikova, Eva $u Centre for Tobacco Dependence, 3rd Medical Department, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic $u Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital Prague, Czech Republic
700    1_
$a Zvolska, Kamila $u Centre for Tobacco Dependence, 3rd Medical Department, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
700    1_
$a Pankova, Alexandra $u Centre for Tobacco Dependence, 3rd Medical Department, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic $u Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital Prague, Czech Republic
700    1_
$a Adamcekova, Zuzana $u Centre for Tobacco Dependence, 3rd Medical Department, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
700    1_
$a Kuhn, Matyas $u Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Noland, Derek $u Behavioral Health and Wellness Program, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
773    0_
$w MED00000153 $t Addiction (Abingdon, England) $x 1360-0443 $g Roč. 116, č. 2 (2021), s. 346-355
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32592219 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133226 $b ABA008
999    __
$a ok $b bmc $g 1714952 $s 1146600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 116 $c 2 $d 346-355 $e 20200718 $i 1360-0443 $m Addiction $n Addiction $x MED00000153
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...